| Similar Articles |
|---|
 |
BusinessWeek
August 30, 2004
Gene G. Marcial |
Martek: Bringing Up Baby Shares of the baby food maker's stock, at 70 in May, fell to 45 in July when worries rose that it might fail to meet demand. The stock is now at 51, as supplies keep rising.   |
The Motley Fool
September 7, 2006
Brian Lawler |
Where's the Love for Martek? What could explain a company reporting a 78% increase in quarterly revenues, yet also being the biggest percentage loser of the day on the Nasdaq? Answer: Guidance for the fourth quarter that is well below what analysts were expecting. |
The Motley Fool
September 5, 2008
Brian Orelli |
The Right Formula in Any Economy Babies have to eat, so nutritional supplement maker Martek Biosciences is still thriving. |
The Motley Fool
September 6, 2007
Markos Kaminis |
The Roller Coaster That Is Martek Martek BioSciences, producer of DHA fatty acid, continues its up-and-down pattern. Most recently, the stock prices collapsed after Q3 reports when the company found itself carrying excess capacity. Long-term investors, this may be a good time to buy. |
The Motley Fool
December 12, 2008
Brian Orelli |
Martek Meanders Through the Year Even though growth seems to be slowing down, Infant-supplement maker Martek Biosciences is in a pretty good position. |
The Motley Fool
February 11, 2009
Rick Aristotle Munarriz |
This IPO Is Hot, Baby Baby formula maker Mead Johnson goes public, snatched from the womb of parent Bristol-Myers Squibb and displayed to the cheering masses. |
The Motley Fool
January 4, 2012
Navjot Kaur |
Mead Johnson Comes Clean Mead Johnson likely to bounce back after its baby formula tested clean. |
The Motley Fool
June 8, 2005
T.G. Wolf |
Popping Martek's Bubble An abundance of algae, used to make the DHA and ARA in baby formula, weighs on this biosciences company. Investors may want to exercise caution here. |
The Motley Fool
November 17, 2009
Brian Orelli |
Up 80%, It's Time to Sell Bristol-Myers to Mead Johnson: It's time to walk on your own. Investors will have an option of exchanging some or all of their Bristol-Myers shares for shares in Mead Johnson for a slight discount |
Nutra Solutions
September 1, 2005 |
Delivering DHA Martek DHA is a vegetarian source of DHA with a ready-made market of moms who know the importance of DHA for brain and eye development. |
The Motley Fool
December 21, 2010
Brian D. Pacampara |
Martek Biosciences Shares Skyrocketed: What You Need to Know Martek Biosciences saw its shares soar a staggering 35% in early Tuesday trading after Dutch vitamin giant Royal DSM NV said it will bid $1.09 billion for the company. |
The Motley Fool
September 17, 2008
Brian Orelli |
IPO? In This Market? Bristol-Myers continues with plans to spin off its nutritionals business. |
The Motley Fool
January 17, 2012
Brian Orelli |
Pharma Focus Is Good For Your Portfolio Build your own portfolio. |
The Motley Fool
December 18, 2007
Brian Orelli |
Bristol-Myers' Sleeker Image Just 12 days after announcing its restructuring plan, Bristol-Myers Squibb has found a buyer for its medical-imaging division and plans to close the deal by the end of next month. |
The Motley Fool
January 29, 2010
Brian Orelli |
All Grown Up, With Cash to Burn Bristol-Myers is all drugs, all the time. |
The Motley Fool
February 19, 2009
Robert Steyer |
IPO Food for Thought The bosses at Pfizer should be interested in the recent Mead Johnson IPO so as to place a value on Wyeth's nutrition business. |
The Motley Fool
January 28, 2009
Brian Orelli |
A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer. |
Prepared Foods
February 4, 2006
Marcia A. Wade |
Loose Lipids While every oil has its "strengths and weaknesses," what matters most is how a particular type of oil affects the Nutrition Facts panel. |
The Motley Fool
December 22, 2011
Rick Aristotle Munarriz |
Recalls Dampen Holiday Cheer Wal-Mart and Target have holiday recalls on their hands. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
October 12, 2009
Robert Steyer |
Healthy Spinoffs, Happy Investors When medical companies spin off unwanted divisions, the spinoffs can outperform the parent. |
The Motley Fool
February 22, 2010
Alex Dumortier |
7 Stocks Hedge Funds Like Hedge funds were battered by losses and investor redemptions during the worst of the financial crisis, but now that the industry has regained some of its swagger, it might be worth asking: Which stocks has the "smart money" been buying? |
The Motley Fool
January 28, 2010
Selena Maranjian |
Spinoffs, Mergers, Taxes, and You An eventful year for your stock could mean fancy tax footwork for you. |
The Motley Fool
December 14, 2009
Rick Aristotle Munarriz |
Rumble in the S&P 500 Jungle By the end of the trading week, Visa and Mead Johnson Nutrition will be added to the S&P 500, where they will take the place of Ciena and MBIA |
The Motley Fool
April 5, 2005
Brian Gorman |
Abbott's Pregnant Opportunity The drug company taps into a significant market with its new products for expecting moms. The firm's unique strategy is worth watching. |
The Motley Fool
December 17, 2009
Brian Orelli |
This Acquisition Hears, Smells, and Tastes Soooo Good Johnson & Johnson picks up an ear, nose, and throat medical device maker. |
The Motley Fool
September 13, 2006
Tim Beyers |
Who's Buying Now? Sometimes insiders are buying for all the right reasons. Who's buying now? Human Genome Sciences... Martek Biosciences... MasterCard... Pinnacle Entertainment... U-Store-It Trust... |
The Motley Fool
October 12, 2004
Brian Gorman |
Abbott's Healthy Diet Is the company's push into nutritional supplements a wise move? |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
January 4, 2010
Rick Aristotle Munarriz |
5 Biggest IPO Winners of 2009 Last year's hottest rookies are unlikely heroes. |
The Motley Fool
April 29, 2009
Brian Orelli |
Parachutes, Cliffs, and Softer Landings Bristol-Myers Squibb faces a major patent cliff in a few years, and it's doing everything it can to make the fall as painless as possible. Early indications from yesterday's first-quarter earnings report look promising. |
The Motley Fool
June 30, 2010
Brian Orelli |
Is Bristol-Myers Squibb a Buy? Bristol-Myers is a better buy than Eli Lilly for one major reason: its resources. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
February 17, 2011
Alex Dumortier |
Seize Your Chance to Beat the Pros! An area of genuine opportunity for the small investor. Spinoffs remain an underappreciated area in which the individual investor actually gains an edge over institutions. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
September 15, 2011
Brian Orelli |
Stop Worrying About Pfizer's Breakup Sometimes you just have to trust management. |
Salon.com
January 25, 2001
Katie Allison Granju |
Did "America's pediatrician" sell out? Attachment parenting guru Dr. William Sears is found to have ties to the infant-formula industry... |
The Motley Fool
March 22, 2010
Rick Aristotle Munarriz |
4 Dividend Stocks Showing You the Money Mead Johnson Nutrition... Garmin... Prospect Capital... Guess?... |
Food Processing
June 2012
Mark Anthony |
Is Algae DHA As Healthy as Fish Oil DHA? A review of research earlier this year found mostly good news in this vegetarian source. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
January 26, 2011
Brian Orelli |
J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot. |
U.S. CPSC
January 22, 2007 |
Next Step Plastic Sippy/Tumbler Cups Recalled for Laceration Hazard The impact of being dropped or banged can cause the cup to break into pieces, resulting in sharp or jagged edges that pose a laceration hazard to children. |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
September 2, 2010
Seth Jayson |
Are Shorts Watching Mead Johnson Nutrition Co.? Will Mead Johnson Nutrition miss its numbers in the next quarter or two? Look here for a clue. |
The Motley Fool
December 29, 2011
Dan Caplinger |
Why the Dow's Moving Higher Today As of midafternoon, all 30 Dow components were higher, with financials again leading the way. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
